# Vector BioPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vector-biopharma

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.vectorbiopharma.com
- Total disclosed funding: $30M
- Latest round: Series A (Aug 10, 2022)
- Investors on record: 1

## About

Based in Basel, Switzerland, and founded in 2021 by its CEO, Lorenz Mayr, and Andreas Plückthun, Vector BioPharma AG, operates as a biopharmaceutical company that offers platform technologies for genetic medicine. In August 2022, Vector BioPharma AG raised USD 30 million in series A funding from investor Versant Ventures.

The company offers a proprietary platform that helps to transform the safety, efficacy, and specificity of tissue-specific delivery and tunable expression of genes and regulators. The company uses capsid shielding technology to help develop genetic medicine and treat important diseases.

The company plans to use the August 2022 funding to support its new gene therapy vector, as well as hire staff and expand its platform.

## Funding rounds

- Series A, Aug 10, 2022, $30M — Versant Ventures

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A